| Name | CFT7455 |
| Description | CFT7455 (Cemsidomide) is an anti-cancer agent showing high affinity to the cereblon E3 ligase with a Kd of 0.9 nM. CFT7455 is an orally active degrader of zinc finger transcription factors Ikaros (IKZF1), and Aiolos (IKZF3). |
| In vitro | CFT7455 enables potent cell growth inhibition in both previously untreated NCIH929 multiple myeloma cell lines with an IC50 of 0.071 nM and NCIH929 cells made resistant to both lenalidomide and pomalidomide with an IC50 of 2.3 nM. CFT7455 promotes the degradation of >75% of steady state IKZF1 in multiple myeloma cells within 1.5 hours at 0.3 nM[1]. |
| In vivo | In mouse xenograft tumor models, CFT7455 (3 μg/kg-100 μg/kg) led to durable tumor regression and demonstrates dose-dependent efficacy[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 20 mg/mL (42.6 mM), Sonication and heating to 60℃ are recommended.
10% DMSO+40% PEG300+5% Tween-80+45% Saline : 2 mg/mL (4.26 mM), Sonication is recommended.
|
| Keywords | orally active | Ligands for E3 Ligase | LigandforE3Ligase | Ligand for E3 Ligase | Inhibitor | inhibit | IKZF3 degrader | IKZF1 | E3 ligase-recruiting Moiety | CFT-7455 | CFT7455 | CFT 7455 | cereblon (CRBN) E3 ligase | cereblon | anti-cancer agent |
| Inhibitors Related | Lenalidomide-Br | Acetyl-cyclosporin A aldehyde | PT-179 | (S)-Thalidomide | BI-3802 | Thalidomide | (S,R,S)-AHPC | Pomalidomide | Amino-PEG1-C2-acid | Lenalidomide | (S,R,S)-AHPC hydrochloride | 5-Aminothalidomide |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library | Transcription Factor-Targeted Compound Library |
United States
